Nanxin Liu
Overview
Explore the profile of Nanxin Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Yang Z, Guo N, Liu N, Zhang Q, Dang X, et al.
RSC Med Chem
. 2024 Sep;
PMID: 39246751
Bcr-Abl is successfully applied to drug discovery as a CML therapeutic target, but point mutation resistance has become a major challenge in the clinical treatment of CML. Our previous studies...
2.
Zhang Q, Liu Y, Li Y, Wang J, Liu N, Zhang J, et al.
Eur J Med Chem
. 2024 Aug;
277:116734.
PMID: 39094275
Proteolysis targeting chimeras (PROTAC) are bifunctional chimeric molecules capable of directly degrading binding proteins through the ubiquitin-proteasome pathway. PROTACs have demonstrated significant potential in overcoming drug resistance and targeting previously...
3.
Li X, Liu N, Li X, Fu G, Huang H
Int J Oral Maxillofac Implants
. 2024 Feb;
39(2):254-262.
PMID: 38394443
Purpose: To evaluate bone preservation and esthetic recovery between the socket-shield technique (SST) with different labial bone plate thicknesses and the conventional immediate implant technique (CIIT). Materials And Methods: Patients...
4.
Liu N, Yang Z, Liu Y, Dang X, Zhang Q, Wang J, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511149
There have been outbreaks of SARS-CoV-2 around the world for over three years, and its variants continue to evolve. This has become a major global health threat. The main protease...
5.
Liu N, Zhong Y, Pang X, Li M, Cannon R, Mei L, et al.
Cell Prolif
. 2023 Apr;
56(10):e13470.
PMID: 37051938
Macrophages' activation plays a central role during the development and progression of inflammation, while the regulation of metabolic reprogramming of macrophages has been recently identified as a novel strategy for...
6.
Si R, Hai P, Zheng Y, Liu N, Wang J, Zhang Q, et al.
Bioorg Med Chem Lett
. 2023 Apr;
87:129275.
PMID: 37030566
Anti-angiogenesis has been proved to be an effective strategy for the treatment of tumors. Anti-angiogenic drugs had achieved certain therapeutic effects. However, drug resistance also gradually emerged and limited the...
7.
Li D, Jiang Y, He P, Li Y, Wu Y, Lei W, et al.
Adv Sci (Weinh)
. 2023 Mar;
10(15):e2207224.
PMID: 36970815
Heterotopic ossification (HO) is a double-edged sword. Pathological HO presents as an undesired clinical complication, whereas controlled heterotopic bone formation by synthetic osteoinductive materials shows promising therapeutic potentials for bone...
8.
Zhang X, Jia L, Liu N, Zhao Y, Zhang T, Xie X
Colloids Surf B Biointerfaces
. 2023 Jan;
222:113134.
PMID: 36630772
The discovery of P-Glycoprotein (P-gp) inhibitors to block chemotherapy drugs efflux is considered an attractive treatment strategy for overcoming cancer multidrug resistance (MDR). Cell membrane biomimetic platform has emerged as...
9.
Zhang Q, Liu N, Wang J, Liu Y, Wang K, Zhang J, et al.
Mol Pharm
. 2023 Jan;
20(2):789-809.
PMID: 36598861
Cancer has become the primary reason for industrial countries death. Although first-line treatments have achieved remarkable results in inhibiting tumors, they could have serious side effects because of insufficient selectivity....
10.
Si R, Liu N, Wang J, Zhang Q, Li Y, Pan X, et al.
Bioorg Med Chem
. 2022 Dec;
77:117115.
PMID: 36508995
Proteolysis-targeting chimeras (PROTACs) is a promising strategy for treatment of various diseases by degrading of disease-related proteins in recent years. Up to now, most PROTAC molecules are mainly aimed at...